Incredible Value. ENTG at about 25% of One Years Revenue...with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for example indicates record first quarter 2022 results:
https://stockhouse.com/news/press-releases/2022/05/30/entourage-health-reports-record-first-quarter-2022-financial-results
Notwithstanding all of the prior major achievements getting us to this point, just within the past few weeks:
-unlike so many cannabis counterparts, ENTG has shored up high level financing guaranteed for more than 2 years with no dilution, and dramatically reduces convertible debentures:
https://stockhouse.com/news/press-releases/2022/07/29/entourage-health-provides-update-on-credit-facilities-maturity-dates-and-amends
-Further expands medical offerings with new products and services:
tockhouse.com/news/press-releases/2022/07/26/entourage-expands-medical-offerings-with-launch-of-new-services-and-products
-Announces and exclusive Canadian licensing deal to distribute a broad range of Irwin Naturals cannabis Products:
https://stockhouse.com/news/press-releases/2022/08/04/irwin-naturals-cannabis-products-to-be-available-in-canada
...and will be introducting groundbreaking Boston Beer/Samuel Adams products at any time now:
https://stockhouse.com/news/press-releases/2022/05/23/the-boston-beer-company-introduces-teapot-a-new-line-of-cannabis-infused-iced
Simply an unrivaled value, period. What a truly extraordinary opportunity here particularly for new investors but again, also for those seeking to cost average as well.